ATLANTA, April 16, 2024 /PRNewswire/ -- Annoviant, Inc., a pioneering company with a breakthrough TxGuard technology platform for soft-tissue healing, currently focused on cardiovascular field, proudly announces receipt of a $2.99 million grant (SBIR Phase 2b) from the National Institutes of Health (NIH). Building upon the Phase II NIH Grant secured in 2021, this funding represents a significant step forward in Annoviants mission to transform the landscape of pediatric cardiac care.Annoviants patented TxGuard stands at the forefront of technological innovation in conduit replacements for treating congenital heart disease (CHD), the most prevalent birth defect globally and a leading cause of birth-related mortality. With an estimated 2.9 million CHD patients in the US alone, the need for advanced solutions is paramount.Addressing critical shortcomings observed in current commercial devices, TxGuard offers unparalleled clinical advantages, notably its resistance to calcification, thrombosis, infection, and the host cell integration. This cutting-edge technology heralds a new era in pediatric cardiac interventions, providing durable pulmonary valved grafts that adapt and regenerate alongside patients, minimizing the need for multiple re-operations over their lifetimes. Driven by the personal experiences of its co-founders, Annoviant is fueled by an unwavering dedication to positively impact the lives and treatment outcomes of congenital heart disease (CHD) patients.